Insider

Bristol Myers Squibb Co.

BMY Health Care · 2 analyses · 11 expectations tracked

Bristol Myers Squibb reported $13.1B in revenue (+6.9% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 11 open management expectations for this company. 1 insider sale recorded. Its latest periodic filing added 62 new risk factors.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

World events

US government funds 6K Inc. as companies cite production risks in reports

The U.S. War Department's Office of Strategic Capital provided a loan to develop domestic production capacity for battery materials. Several public companies describe in their reports how investments in manufacturing and the availability of critical minerals affect their operations.

Company history

October 2026

BRISTOL MYERS SQUIBB CO: 12 recorded developments from 1 official source in 2026-10.

  • 2026-10-29: Revenue (us-gaap:Revenues), quarter 2026-07-01 to 2026-09-30: 13,069,000,000 USD (13.1 billion; 13,069 million); same period a year earlier (2025-07-01 to 2025-09-30): 12,222,000,000 USD (12.2 billion; 12,222 million); change +6.9% Source
  • 2026-10-29: Revenue (us-gaap:Revenues), year to date 2026-01-01 to 2026-09-30: 37,532,000,000 USD (37.5 billion; 37,532 million); same period a year earlier (2025-01-01 to 2025-09-30): 35,692,000,000 USD (35.7 billion; 35,692 million); change +5.2% Source
  • 2026-10-29: Net income (us-gaap:NetIncomeLoss), quarter 2026-07-01 to 2026-09-30: 2,162,000,000 USD (2.2 billion; 2,162 million); same period a year earlier (2025-07-01 to 2025-09-30): 2,201,000,000 USD (2.2 billion; 2,201 million); change -1.8% Source
  • 2026-10-29: Net income (us-gaap:NetIncomeLoss), year to date 2026-01-01 to 2026-09-30: 8,156,000,000 USD (8.2 billion; 8,156 million); same period a year earlier (2025-01-01 to 2025-09-30): 5,967,000,000 USD (6 billion; 5,967 million); change +36.7% Source
  • 2026-10-29: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), quarter 2026-07-01 to 2026-09-30: 2,365,000,000 USD (2.4 billion; 2,365 million); same period a year earlier (2025-07-01 to 2025-09-30): 2,528,000,000 USD (2.5 billion; 2,528 million); change -6.4% Source
  • 2026-10-29: Research and development expense (us-gaap:ResearchAndDevelopmentExpense), year to date 2026-01-01 to 2026-09-30: 7,973,000,000 USD (8 billion; 7,973 million); same period a year earlier (2025-01-01 to 2025-09-30): 7,365,000,000 USD (7.4 billion; 7,365 million); change +8.3% Source
  • 2026-10-29: Operating cash flow (us-gaap:NetCashProvidedByUsedInOperatingActivities), year to date 2026-01-01 to 2026-09-30: 8,678,000,000 USD (8.7 billion; 8,678 million); same period a year earlier (2025-01-01 to 2025-09-30): 12,182,000,000 USD (12.2 billion; 12,182 million); change -28.8% Source
  • 2026-10-29: Capital expenditure (us-gaap:PaymentsToAcquirePropertyPlantAndEquipment), year to date 2026-01-01 to 2026-09-30: 996,000,000 USD (996 million); same period a year earlier (2025-01-01 to 2025-09-30): 941,000,000 USD (941 million); change +5.8% Source
  • 2026-10-29: Cash and cash equivalents (us-gaap:CashAndCashEquivalentsAtCarryingValue), as of 2026-09-30: 9,574,000,000 USD (9.6 billion; 9,574 million); previous balance (2025-12-31): 10,209,000,000 USD (10.2 billion; 10,209 million); change -6.2% Source
  • 2026-10-29: Total liabilities (us-gaap:Liabilities), as of 2026-09-30: 65,368,000,000 USD (65.4 billion; 65,368 million); previous balance (2025-12-31): 71,533,000,000 USD (71.5 billion; 71,533 million); change -8.6% Source
  • 2026-10-29: Shareholders' equity (us-gaap:StockholdersEquity), as of 2026-09-30: 23,404,000,000 USD (23.4 billion; 23,404 million); previous balance (2025-12-31): 18,473,000,000 USD (18.5 billion; 18,473 million); change +26.7% Source
  • 2026-10-29: Long-term debt (us-gaap:LongTermDebtNoncurrent), as of 2026-09-30: 41,849,000,000 USD (41.8 billion; 41,849 million); previous balance (2025-12-31): 42,850,000,000 USD (42.9 billion; 42,850 million); change -2.3% Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended September 30, 2026, filed October 29, 2026. SEC

LatestEarlierChange
Revenue quarter$13.1B$12.2B+6.9%
Net income quarter$2.2B$2.2B-1.8%
Diluted EPS quarter$1.05$1.08-2.8%
Dividends per share quarter$0.63$0.62+1.6%
Operating cash flow year to date$8.7B$12.2B-28.8%
Cash and cash equivalents balance$9.6B$10.2B-6.2%
Long-term debt balance$41.8B$42.9B-2.3%

Next results expected around January 28, 2027 (estimate: the quarter ending about December 30, 2026 plus the 29 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Revenue by quarter, $B

12.3Q4 '24*11.2Q1 '2512.3Q2 '2512.2Q3 '2512.5Q4 '25*11.5Q1 '2613Q2 '2613.1Q3 '26
Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Bristol Myers Squibb Co. BMY$13.1B+6.9%—
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Bristol Myers Squibb increased its full-year, non-GAAP revenue guidance to a range of approximately $49.75 billion to $50.25 billion.

    Said October 29, 2026 · Source · Our article

    Not yet checked against later reports.

  • The company plans to develop a new manufacturing campus at Generation Park in Houston, Texas, with a $2.3 billion investment and creation of nearly 500 jobs.

    Said October 29, 2026 · Source · Our article

    Not yet checked against later reports.

  • Significant NME registrational data is expected in 2026, including for Admilparant IPF, Arlo-cel 4L+ MM, and Iberdomide RRMM PFS.

    Said October 29, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company expects to report Sotyktu SLE (POETYK SLE-1 & 2) LCM pivotal data.

    Said October 29, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Non-GAAP EPS is expected to be in a range of $6.35 - $6.55, inclusive of a $(0.60) impact from Acquired IPRD and licensing income.

    Said October 29, 2026 · Source · Our article

    Not yet checked against later reports.

  • The company expects 2026 Worldwide Eliquis revenue growth of 20% - 25% compared to 2025.

    Said October 29, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

Show all (11)
  • The company expects total Worldwide Eliquis revenues to increase in 2026 when compared to 2025.

    Said October 29, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • RayzeBio, Inc. plans to invest more than $173 million to expand its radiopharmaceutical manufacturing operations by establishing a new facility in Whitestown, Indiana, with construction expected to begin this year.

    Said October 29, 2026 · Source · Our article

    Not yet checked against later reports.

  • The company raised its 2026 revenue guidance to a range of $49.75 billion to $50.25 billion.

    Said October 29, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • The company updated its non-GAAP EPS guidance range to $6.35 to $6.55, inclusive of a $(0.60) per share net impact from Acquired IPRD charges and licensing income.

    Said October 29, 2026 · Period named: 2026 · Source · Our article

    Not yet checked against later reports.

  • Full-year other income/expense is expected to be approximately $650 million of expense.

    Said October 29, 2026 · Source · Our article

    Not yet checked against later reports.

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Changes in risk factors

The 10-Q filed October 29, 2026 compared with the 10-Q filed July 30, 2026: risk paragraphs that were added or dropped, quoted as filed. SEC

Added (62)

  • The FDA expanded approval of Camzyos for the treatment of symptomatic oHCM to improve functional capacity and symptoms in adults and pediatric patients weighing 30 kg (66 lbs) or more.
  • FDA approval of Zenbexus (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with MM who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
  • | Three Months Ended September 30, | | Nine Months Ended September 30,

Dropped (47)

  • | 3,664 | | | 3,481 | | | 5 | % | | 2 | % | | 7,108 | | | 6,590 | | | 8 | % | | 4 | %
  • | 318 | | | 270 | | | 18 | % | | (3) | % | | 575 | | | 488 | | | 18 | % | | (5) | %
  • U.S. | 34 | % | | 52 | % | | (18) | % | | 36 | % | | 52 | % | | (16) | %

Found by comparing the two reports paragraph by paragraph, without AI. A new or dropped risk is not by itself a sign of trouble.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 5, 2026Julia A HallerSale3,800$63.31$240,578SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock173,661,963$10,836,506,510-3.7%Q3 2026
State Street103,335,618$6,448,142,563+0.9%Q3 2026
Geode Capital Management50,641,973$3,151,221,305-10.3%Q3 2026
Norges Bank (Norway's sovereign fund)36,866,658$2,124,256,834—Q2 2026
Fidelity (FMR)28,317,459$1,767,009,468+73.8%Q3 2026
Two Sigma Investments7,879,742$491,695,901-21.9%Q3 2026
Wellington Management5,524,147$344,706,773+41.1%Q3 2026
Millennium Management2,203,471$137,496,590+192.8%Q3 2026
D. E. Shaw & Co.1,146,297$71,528,933+104.9%Q3 2026
Citadel Advisors1,142,914$71,317,833-27.3%Q3 2026
Bridgewater Associates77,808$4,855,219-67.8%Q3 2026
T. Rowe Price27,528,350$1,717,770-13.2%Q3 2026
Renaissance Technologies18,200$1,135,680-98.1%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.